Perspectives
CGRP for migraine prevention may reduce use of acute medications
Use of CGRP receptor blockers is associated with a reduction in opioid claims
March 21, 2019Use of calcitonin gene-related peptide (CGRP) receptor blockers for migraine prevention is associated with a reduction in opioid claims
This study tracked growth of the use of CGRP receptor blockers from their first approval in 2018. Annual wholesale cost is estimated at $7,200. The number of members who started on a new CGRP prescription increased steadily from six members in May 2018, to more than 1,800 members in July 2019, which is about 125 new users added per month. CGRP drug costs are expected to reach $15 million per month by the end of 2020 – triple the cost seen in July 2019.
Of the members taking CGRP, Prime saw a 5 percent reduction in members with an opioid claim. The number of members with a triptan pharmacy claim decreased by nearly 10 percent in the same time period. These reductions in the use of acute medications among individuals who take CGRP treatments as directed for over six months is an important finding.
Related news
Perspectives
April 24, 2024
Prime/MRx resident wins AMCP Foundation Best Poster Award
Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes
Perspectives
April 23, 2024
Expert Clinical Network Insights: April 2024
A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance
Perspectives
April 23, 2024
April Fraud Focus – How to prioritize drug safety at home
While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…